Common Nonsynonymous Substitutions in SLCO1B1 Predispose to Statin Intolerance in Routinely Treated Individuals With Type 2 Diabetes: A Go-DARTS Study
- 22 December 2010
- journal article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 89 (2), 210-216
- https://doi.org/10.1038/clpt.2010.255
Abstract
SLCO1B1 gene variants are associated with severe statin‐induced myopathy. We examined whether these variants are also associated with general statin intolerance in a large population of patients with type 2 diabetes receiving statins as part of routine clinical care. A total of 4,196 individuals were genotyped for rs4149056 (Val174Ala) and rs2306283 (Asp130Asn). Intolerance was defined by serum biochemistry and also by discontinuation, switching, or reduction in dose of the prescribed statin drug. Ala174 was associated with higher intolerance (odds ratio = 2.05, P = 0.043), whereas Asp130 was associated with lower intolerance (odds ratio = 0.71, P = 0.026). Ala174 was associated with a lower low‐density lipoprotein cholesterol (LDLc) response to statins (P = 0.01) whereas 130D was associated with a greater LDLc response to statins (P = 0.048), as previously reported; however, this association was no longer present when data for statin‐intolerant individuals were removed from the analysis. This study suggests that common genetic variants selected for an extreme phenotype of statin‐induced myopathy also predispose to more common milder statin intolerance and may, for this reason, impact lipid‐lowering efficacy. Clinical Pharmacology & Therapeutics (2011) 89 2, 210–216. doi:10.1038/clpt.2010.255Keywords
This publication has 27 references indexed in Scilit:
- The SLCO1B1*5Genetic Variant Is Associated With Statin-Induced Side EffectsJournal of the American College of Cardiology, 2009
- A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS studyPharmacogenetics and Genomics, 2008
- SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide StudyThe New England Journal of Medicine, 2008
- Long‐term adherence to statin treatment in diabetesDiabetic Medicine, 2008
- Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS studyPharmacogenetics and Genomics, 2008
- SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acidPharmacogenetics and Genomics, 2006
- High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)Pharmacogenetics, 2004
- Polymorphisms in OATP-COnline Journal of Public Health Informatics, 2001
- Integrating genotype and phenotype information: an overview of the PharmGKB projectThe Pharmacogenomics Journal, 2001
- Long-term efficacy and tolerability of simvastatin in a large cohort of elderly hypercholesterolemic patientsAtherosclerosis, 1995